NCT00160329View on ClinicalTrials.gov

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

PHASE3CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

March 31, 2009

Conditions

HyperlipidemiaHIV Infections

Interventions

DRUG

Atazanavir

300 mg with ritonavir boosting or 400 mg without

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Stanford University

OTHER